Skip to main content
SpringerLink
Log in

Cancer Chemotherapy and Selective Drug Development

Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983

  • Conference proceedings
  • © 1984

Overview

Editors:
  1. K. R. Harrap
    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. W. Davis
    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. A. H. Calvert
    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Oncology (DION, volume 23)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (129 papers)

  1. Front Matter

    Pages i-xxv
    Download chapter PDF

  2. Advances in Cancer Treatment

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. New Approaches to Old Problems

      1. Clinical Drug Resistance
        • J. M. A. Whitehouse
        Pages 5-11
      2. New Therapies With Old Drugs
        • I. E. Smith
        Pages 13-17
      3. Antimetabolite Combinations Possessing Enhanced Efficacy
        • M. H. N. Tattersall
        Pages 19-32
      4. Mismatched Bone Marrow Transplantation
        • R. Powles, G. Goss, A. Pedrazzini, M. Crofts, H. Clink, J. Millar et al.
        Pages 33-41
      5. Prospects for Immunotherapy
        • P. Alexander
        Pages 43-45

    3. Current Clinical Progress with New Agents

      1. Platinum Analogs
        • S. K. Carter
        Pages 49-53
      2. Mitoxantrone: A Promising New Agent for the Treatment of Human Cancer
        • Colin P. Turnbull, David Jackson
        Pages 55-63
      3. Current Clinical Progress — Podophyllotoxins
        • Brian F. Issell
        Pages 65-69
      4. Pharmacology of Nitrosourea Anticancer Agents
        • Ann L. Wang, Philip S. Schein
        Pages 71-75
      5. Current Clinical Progress with New Agents: Alkylating Agents
        • S. Eckhardt
        Pages 77-82
      6. Interferon
        • J. L. Toy
        Pages 83-87

    4. Drug Treatment of Specific Cancers

      1. Chemotherapy of Lung Cancer
        • H. H. Hansen
        Pages 91-94
      2. Hormone-Chemotherapy in Treatment of Advanced Breast Cancer
        • F. Cavalli, A. Goldhirsch, R. Joss, K. W. Brunner
        Pages 95-104
      3. Chemotherapy of Ovarian Cancer
        • E. Wiltshaw
        Pages 105-109
      4. Obstacles to Improved End-Results in Head and Neck Cancer
        • R. E. Wittes
        Pages 111-115
      5. Treatment of Disseminated Malignant Lymphoma
        • T. A. Lister, H. S. Dhaliwal
        Pages 117-122
      6. Malignant Disease in Childhood
        • M. G. Mott
        Pages 123-133
      7. Chemotherapy of Disseminated Testicular Cancer
        • Lawrence H. Einhorn
        Pages 135-139
Back to top

Keywords

About this book

Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.

Bibliographic Information

  • Book Title: Cancer Chemotherapy and Selective Drug Development

  • Book Subtitle: Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983

  • Editors: K. R. Harrap, W. Davis, A. H. Calvert

  • Series Title: Developments in Oncology

  • DOI: https://doi.org/10.1007/978-1-4613-3837-6

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishing, Boston 1984

  • Hardcover ISBN: 978-0-89838-673-8Published: 31 August 1984

  • Softcover ISBN: 978-1-4613-3839-0Published: 17 October 2011

  • eBook ISBN: 978-1-4613-3837-6Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XXVI, 585

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation